APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 1:500~1:1000 |
| 1:50~1:100 |
Not tested in other applications.
Calculated MW
Product Note
Factor VII (cleaved Arg212) antibody detects endogenous levels of fragment of activated FA7 resulting from cleavage adjacent to Arg212.
PROPERTIES
Form
Liquid
Buffer
PBS, 150mM NaCl, 50% Glycerol
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
The antiserum was produced against synthesized peptide derived from human Factor VII (171-220).
Purification
Purified by antigen-affinity chromatography
From serum
Conjugation
Unconjugated
Note
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET
Synonyms
F7 , SPCA , coagulation factor VII , Factor VII , FVII
Cellular Localization
Secreted
Background
This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Defects in this gene can cause coagulopathy. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015]
Database
Research Area
DATA IMAGES
|
GTX86939 WB Image
WB analysis of Jurkat cells treated with etoposide using GTX86939 Factor VII (cleaved Arg212) antibody.
|
|
|
GTX86939 IHC-P Image
IHC-P analysis of human breast carcinoma tissue using GTX86939 Factor VII (cleaved Arg212) antibody. The picture on the right is blocked with the synthesized peptide.
|
REFERENCE
There are currently no references for Factor VII (cleaved Arg212) antibody (GTX86939). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Factor VII (cleaved Arg212) antibody (GTX86939). Be the first to share your experience with this product.
